Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 6/20 | 0.35 |
| ▸ | LTA4H | P09960 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12099900 | 0.83 | PKM (0.39) | L3MBTL1NPC1RAB9APPARGPPARA | |
| SCHEMBL1305402 | 0.83 | KIF11 (0.34) | KIF11LTA4HL3MBTL1NPC1RAB9A | |
| SCHEMBL1078041 | 0.66 | ALDH1A1 (0.43) | L3MBTL1NPC1RAB9APPARGPPARA | |
| SCHEMBL1304403 | 0.66 | MAPT (0.36) | NPC1RAB9A | |
| SCHEMBL12468595 | 0.64 | PARP10 (0.39) | L3MBTL1NPC1RAB9A | |
| SCHEMBL6544667 | 0.60 | ALDH1A1 (0.41) | NPC1RAB9A | |
| SCHEMBL5309684 | 0.59 | ALPL (0.44) | L3MBTL1NPC1RAB9APPARGPPARA | |
| SCHEMBL5082950 | 0.59 | LTA4H (0.53) | KIF11LTA4HPPARGPPARA | |
| SCHEMBL5082944 | 0.59 | LTA4H (0.53) | KIF11LTA4HPPARGPPARA | |
| SCHEMBL9090603 | 0.59 | LTA4H (0.53) | KIF11LTA4HPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048896-B2 | Inhibit nonenzymatic formation of advanced glycation end-products (AGE) using e.g. aminoguanidine, OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide], pyridoxamine, antioxidants, alagebrium, antihypertensives, angiotensin-converting enzyme inhibitors | Cell Viable Corporation (US) | 2011-11-01 | — | — | US | claimed |
| US-6605642-B2 | Administering specified compounds which are derivatives of phenoxyisobutyric acids and of benzoic acid including aryl and heterocyclic ureido derivatives and aryl and heterocyclic carboxamido derivatives; treating aging, arthritis, diabetes | CITY OF HOPE | 2003-08-12 | — | — | US | claimed |
| US-8053449-B2 | Method for inhibiting AGE complex formation | Cell Viable Corporation (US) | 2011-11-08 | — | — | US | disclosed |
| US-8048896-B2 | Inhibit nonenzymatic formation of advanced glycation end-products (AGE) using e.g. aminoguanidine, OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide], pyridoxamine, antioxidants, alagebrium, antihypertensives, angiotensin-converting enzyme inhibitors | Cell Viable Corporation (US) | 2011-11-01 | — | — | US | disclosed |
| US-20080076804-A1 | METHODS FOR INHIBITING AND BREAKING AGE COMPLEX FORMATION | Cell Viable Corporation | 2008-03-27 | — | — | US | disclosed |
| US-20070099966-A1 | Device and Method for Inhibiting AGE Complex Formation | Cell Viable Corporation | 2007-05-03 | — | — | US | disclosed |
| WO-2007044309-A2 | DEVICE AND METHOD FOR INHIBITING AGE COMPLEX FORMATION | VASIX CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |